Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase <scp>II</scp> trial

Zhang, Mingzhi; Song, Wei; Cai, Qingqing; Zhang, Liling; Sun, Xiuhua; Zou, Liqun; Zhang, Huilai; Wang, Lili; Hou, Xue

doi:10.1002/ajh.26499

Cited by 28 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multicenter phase II trial applied chidamide in combination with prednisone, etoposide, and thalidomide for a total of 8 cycles in untreated angioimmunoblastic T‐cell lymphoma patients. The results showed that an ORR of 90.2% and complete remission (CR) of 54.9%, respectively 32 . The 2‐year rate of PFS and OS were 66.5% and 82.2%, respectively.…”

Section: Chidamide In Non‐hodgkin's Lymphomamentioning

confidence: 99%

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Cao

Xue

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

Epigenetic alterations frequently participate in the onset of hematological malignancies. Histone deacetylases (HDACs) are essential for regulating gene transcription and various signaling pathways. Targeting HDACs has become a novel treatment option for hematological malignancies. Chidamide is the first oral selective HDAC inhibitor for HDAC1, HDAC2, HDAC3, and HDAC10 and was first approved for the treatment of R/R peripheral T‐cell lymphoma by the China Food and Drug Administration in 2014. Chidamide was also approved under the name Hiyasta (HBI‐8000) in Japan in 2021. In vitro studies revealed that chidamide could inhibit proliferation and induce apoptosis via cell cycle arrest and the regulation of apoptotic proteins. In clinical studies, chidamide was also efficacious in multiple myeloma, acute leukemia and myelodysplastic syndrome. This review includes reported experimental and clinical data on chidamide monotherapy or chidamide treatment in combination with chemotherapy for various hematological malignancies, offering a rationale for the renewed exploration of this drug.

show abstract

Section: Chidamide In Non‐hodgkin's Lymphomamentioning

confidence: 99%

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Cao

Xue

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…As a listed therapeutic drug for peripheral T‐cell lymphoma, chidamide is also included. Chidamide combined with chemotherapy can improve the median progression‐free survival of patients, and it is the first approved oral subtype selective HDACI in China 393,394 . HDACIs have also been found to be effective in treating multiple myeloma.…”

Section: Therapeutic Enzyme Targets In Ptms Of Histonesmentioning

confidence: 99%

“…Chidamide combined with chemotherapy can improve the median progression‐free survival of patients, and it is the first approved oral subtype selective HDACI in China. 393 , 394 HDACIs have also been found to be effective in treating multiple myeloma. The combination of panobinostat with bortezomib and dexamethasone was approved by the FDA in 2015 for patients who had received at least two treatment programs before.…”

Section: Therapeutic Enzyme Targets In Ptms Of Histonesmentioning

confidence: 99%

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets

Liu

Guo

et al. 2023

MedComm

View full text Add to dashboard Cite

Histones are DNA‐binding basic proteins found in chromosomes. After the histone translation, its amino tail undergoes various modifications, such as methylation, acetylation, phosphorylation, ubiquitination, malonylation, propionylation, butyrylation, crotonylation, and lactylation, which together constitute the “histone code.” The relationship between their combination and biological function can be used as an important epigenetic marker. Methylation and demethylation of the same histone residue, acetylation and deacetylation, phosphorylation and dephosphorylation, and even methylation and acetylation between different histone residues cooperate or antagonize with each other, forming a complex network. Histone‐modifying enzymes, which cause numerous histone codes, have become a hot topic in the research on cancer therapeutic targets. Therefore, a thorough understanding of the role of histone post‐translational modifications (PTMs) in cell life activities is very important for preventing and treating human diseases. In this review, several most thoroughly studied and newly discovered histone PTMs are introduced. Furthermore, we focus on the histone‐modifying enzymes with carcinogenic potential, their abnormal modification sites in various tumors, and multiple essential molecular regulation mechanism. Finally, we summarize the missing areas of the current research and point out the direction of future research. We hope to provide a comprehensive understanding and promote further research in this field.

show abstract

“…Quality assessments for individual studies using a modi ed Downs and Black checklist are provided in the Table 2. Frontiers in Immunology g 22 [10] Newlydiagnosed Phase 2 NCT03273452 chidamide +prednisone,+etoposide+thalidomide 68 49(72%) 63(25-83) American Journal of Hematology g 21 [11] Newlydiagnosed Phase 2)and 65.8%(95% CI, 54.4-75.6%, Figure 2), respectively;the CR rates and ORR rate of 7 trials were highly heterogeneous (Q=74.026, I 2 = 90.544%,, P=0.000, Figure 2A Q=65.065, I 2 = 89.242%,, P=0.000, Figure 2B).…”

Section: Study Characteristics and Quality Assessmentmentioning

confidence: 99%

Chidamide as monotherapy and in combination with traditional chemotherapy in peripheral T-cell lymphoma：a systematic review and meta-analysis

yang

Yao

2022

Preprint

View full text Add to dashboard Cite

Background:Traditional chemotherapy regimens are not ideal for the treatment of peripheral T-cell lymphoma(PTCL). Recent clinical data have shown Chidamide,a type of histone deacetylase inhibitors, as a new type of anti-tumor drug, have achieved remarkable results in the treatment of PTCL.Therefore, we performed a systematic literature review and meta-analysis to objectively assess the efficacy and safety for peripheral T-cell lymphoma treated with Chidamide alone or Chidamide combination with chemotherapy. Methods:We searched systematically for studies from the databases of PubMed, Embase, and the Cochrane Library published were searched without language restriction from inception until June 2022.using the following combination of free-text terms linked by Boolean operators: “peripheral T-cell lymphoma”OR“PTCL”OR“angioimmunoblastic lymphoma”OR“anaplastic large cell lymphoma”OR“NK/T-cell lymphoma”AND“Chidamide”. The primary end points were complete remission and overall response rates, adverse events were the secondary end points. Results: A total of 7 clinical trials including newly-diagnosed and relapsed or refractory PTCL patients were analyzed.The overall CR rate was 35.2%(95% CI, 24.2-48%, Figure 2). And the ORR was 65.8%(95% CI, 54.4-75.6%). Thrombocytopenia, anemia, neutropenia were the most common grade 3 and 4 AEs. Conclusion: Chidamide is effective for PTCL, and its efficacy can be increased with the combination traditional chemotherapy.

show abstract

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial

Cited by 28 publications

References 52 publications

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets

Chidamide as monotherapy and in combination with traditional chemotherapy in peripheral T-cell lymphoma：a systematic review and meta-analysis

Contact Info

Product

Resources

About